An interventional study of Progressive Muscle Relaxation (PMR) in Diabetes Mellitus and Diabetes Mellitus Type 2, sponsored by Al-Zaytoonah University of Jordan. Completed at 1 site in Jordan. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Al-Zaytoonah University of Jordan · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan — 2 open to participants now, 3 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Jordan.
Among the 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 24th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan are open now. Recruiting first, the newest first:
Universiti Sains Malaysia · Sites in Jordan
Ages 18+ · Healthy volunteers
Jerash Private University · Sites in Jordan
Ages 18+
A study can be open while its sites in Jordan have not opened yet or have stopped. Only those recruiting at a site in Jordan →
Of the 881 Diabetes Mellitus, Type 2 studies recruiting now, 375 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 96 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 178 across the 18 interventional studies, 3,122 across the 6 observational. Of the 19 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
Al-Zaytoonah University of Jordan is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Al-Zaytoonah University of Jordan has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes Mellitus, Type 2 with a site in Jordan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795918Universiti Sains MalaysiaPREDICT-DM: Community Pharmacy-Based Point-of-Care Testing for Undiagnosed T2DM | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Diabetes Mellitus, Type 2 with a site in Jordan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of progressive muscle relaxation (PMR) on neuropathic pain and fatigue among elderly patients with diabetes mellitus.
Diabetic neuropathy can cause pain, discomfort, and fatigue, which may negatively affect the daily activities and quality of life of older adults. Progressive muscle relaxation is a non-pharmacological technique that involves systematically tensing and relaxing different muscle groups to promote physical relaxation and reduce discomfort.
The study includes 96 elderly patients with diabetes mellitus who are divided into two groups. The intervention group receives progressive muscle relaxation in addition to routine care, while the control group receives routine care alone.
Neuropathic pain is assessed using the Douleur Neuropathique 4 (DN4) questionnaire and the Numeric Pain Rating Scale (NPRS). Fatigue is assessed using the Fatigue Severity Scale (FSS).
The study evaluates whether progressive muscle relaxation can reduce neuropathic pain and fatigue severity among elderly patients with diabetes mellitus.
Diabetes mellitus is a chronic metabolic condition associated with several complications, including diabetic peripheral neuropathy. Neuropathic pain is a common and distressing complication that may interfere with sleep, mobility, daily activities, and overall well-being. Fatigue is another frequently reported symptom among older adults with diabetes and may further affect their functional independence and quality of life.
Progressive muscle relaxation (PMR) is a non-pharmacological relaxation technique involving the systematic tensing and subsequent relaxing of different muscle groups. It is intended to promote physical relaxation, reduce muscular tension, and support the management of pain and fatigue.
This quasi-experimental study uses a study-control group design to evaluate the effect of progressive muscle relaxation on neuropathic pain and fatigue among elderly patients with diabetes mellitus.
The study will be conducted at the diabetes clinic of Abu Bakr Al-Siddiq Clinics Complex, affiliated with the General Authority for Health Insurance, in Shebin El-Kom, Menoufia Governorate, Egypt.
A purposive sample of 96 elderly patients with diabetes mellitus will participate. Participants are allocated into two equal groups:
Data collection instruments include:
The primary focus is to evaluate changes in neuropathic pain and fatigue following the progressive muscle relaxation intervention. The study also examines the relationship between neuropathic pain and fatigue severity.
The findings may contribute to evidence regarding the use of simple, non-pharmacological nursing interventions to support symptom management among elderly patients living with diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,415 are open to participants now.
This study's enrollment of 96 is above the median of 80 across 8,365 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Al-Zaytoonah University of Jordan is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
**Inclusion Criteria:**
**Exclusion Criteria:** Participants with conditions that prevent them from safely performing the progressive muscle relaxation exercises, if specified in the approved study protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group (n=48) receive progressive muscle relaxation (PMR) training in addition to routine care. The intervention involves systematic tensing and relaxing of different muscle groups to promote relaxation and help reduce neuropathic pain and fatigue associated with diabetes mellitus. Participants receive the intervention according to the study protocol. Neuropathic pain and fatigue are assessed using the Douleur Neuropathique 4 (DN4) questionnaire, Numeric Pain Rating Scale (NPRS), and Fatigue Severity Scale (FSS).
Behavioral: Progressive Muscle Relaxation (PMR)
Participants in this group (n=48) receive routine care provided at the diabetes clinic without the progressive muscle relaxation intervention. Neuropathic pain and fatigue are assessed using the same study instruments as the intervention group: the Douleur Neuropathique 4 (DN4) questionnaire, Numeric Pain Rating Scale (NPRS), and Fatigue Severity Scale (FSS).
Progressive muscle relaxation (PMR) is a structured behavioral relaxation technique involving the systematic tensing and subsequent relaxing of different muscle groups. It is provided to elderly patients with diabetes mellitus as a non-pharmacological nursing intervention intended to promote relaxation and help manage neuropathic pain and fatigue. The intervention is delivered to participants in the experimental group in addition to routine diabetes care, according to the study protocol. The control group receives routine care without PMR.
Change in Neuropathic Pain Severity
Neuropathic pain severity will be assessed using the Numeric Pain Rating Scale (NPRS), a scale ranging from 0 (no pain) to 10 (worst imaginable pain). Changes in pain scores will be evaluated by comparing measurements before and after the intervention between the progressive muscle relaxation group and the routine care group.
Time frame: Baseline and immediately after completion of the intervention
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Jan 2026, 4 months.
Of 2,070 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 4 months is below that.
Counting every sponsor, half of 2,247 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al-Zaytoonah University of Jordan